Sotera Health announces a secondary offering of 30 million shares by Warburg Pincus and GTCR, with Goldman Sachs as underwriter.
Quiver AI Summary
Sotera Health Company has announced the launch of a secondary offering of 30 million shares of its common stock, which will be sold by certain affiliates of Warburg Pincus LLC and GTCR LLC, with no shares being sold by the company itself. As the company will not receive any proceeds from this offering, it will cover the related expenses under its registration rights agreement. Goldman Sachs & Co. LLC is serving as the underwriter for the offering. The registration statement for this offering was previously filed with the SEC, and the prospectus will be made available to interested parties. This press release contains forward-looking statements and highlights the company's commitment to providing essential sterilization solutions and services in the healthcare sector.
Potential Positives
- The secondary offering of 30,000,000 shares indicates strong interest from major financial players, suggesting confidence in the company's future prospects.
- The involvement of reputable underwriters like Goldman Sachs & Co. LLC adds credibility to the offering and helps attract potential investors.
- The fact that the offering is solely by selling stockholders can indicate that the company is not diluting its own share value, potentially maintaining shareholder confidence.
- The press release reaffirms Sotera Health's position as a leader in providing critical sterilization and lab testing solutions, reinforcing its brand value in the healthcare industry.
Potential Negatives
- The company is not benefiting from the proceeds of the offering since all shares are being sold by affiliates, raising concerns about the financial strategy and potential liquidity challenges.
- The necessity of a secondary offering could signal to investors that the company's stock may be overvalued or that there are issues fueling the need for additional shares in circulation.
- The fact that the company will cover the expenses of the offering could further strain its financial resources, suggesting possible financial instability or cash flow issues.
FAQ
What is the primary purpose of Sotera Health's secondary offering?
Sotera Health's secondary offering aims to sell 30,000,000 shares of common stock from affiliates of Warburg Pincus and GTCR.
Who is underwriting the secondary offering?
Goldman Sachs & Co. LLC is acting as the underwriter for Sotera Health's secondary offering.
Will Sotera Health receive proceeds from the offering?
No, Sotera Health will not receive any proceeds from the secondary offering.
How can investors obtain the preliminary prospectus?
Investors can get the preliminary prospectus from Goldman Sachs at their New York office or by contact via phone or email.
What does the forward-looking statement disclaimer indicate?
The disclaimer informs that forward-looking statements involve risks and uncertainties, and outcomes may differ from expectations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SHC Insider Trading Activity
$SHC insiders have traded $SHC stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SHC stock by insiders over the last 6 months:
- PINCUS & CO. WARBURG has made 0 purchases and 2 sales selling 24,000,000 shares for an estimated $362,664,000.
- INVESTMENT XI LLC GTCR sold 8,000,000 shares for an estimated $120,888,000
- MICHAEL P RUTZ (President of Sterigenics) sold 126,611 shares for an estimated $2,074,305
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SHC Hedge Fund Activity
We have seen 154 institutional investors add shares of $SHC stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TPG GP A, LLC removed 6,786,110 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $75,461,543
- SCULPTOR CAPITAL LP added 2,462,489 shares (+27.2%) to their portfolio in Q2 2025, for an estimated $27,382,877
- ARROWMARK COLORADO HOLDINGS LLC removed 1,867,829 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $20,770,258
- POINT72 (DIFC) LTD added 1,136,326 shares (+192.6%) to their portfolio in Q2 2025, for an estimated $12,635,945
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,101,604 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,249,836
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,007,963 shares (+12.5%) to their portfolio in Q2 2025, for an estimated $11,208,548
- KHROM CAPITAL MANAGEMENT LLC added 988,801 shares (+174.1%) to their portfolio in Q2 2025, for an estimated $10,995,467
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SHC Analyst Ratings
Wall Street analysts have issued reports on $SHC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/02/2025
To track analyst ratings and price targets for $SHC, check out Quiver Quantitative's $SHC forecast page.
$SHC Price Targets
Multiple analysts have issued price targets for $SHC recently. We have seen 3 analysts offer price targets for $SHC in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Jason Bednar from Piper Sandler set a target price of $17.0 on 11/05/2025
- Luke Sergott from Barclays set a target price of $20.0 on 11/05/2025
- Casey Woodring from JP Morgan set a target price of $16.0 on 11/05/2025
Full Release
CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.
Goldman Sachs & Co. LLC is acting as the underwriter for the Offering.
The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by email at [email protected] .
A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements:
Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACT:
Jason Peterson
Vice President, Investor Relations, Sotera Health
[email protected]
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer, Sotera Health
[email protected]
Source: Sotera Health Company
